MBF Life Limited v Rowena Marchant
[2006] NSWCA 363
At a glance
Source factsCourt
Court of Appeal (NSW)
Decision date
2006-09-07
Before
Handley JA, Beazley JA, Santow JA
Source
Original judgment source is linked above.
Judgment (11 paragraphs)
Background 9 The factual circumstances surrounding the death of Mr Marchant can be stated briefly. Mr Marchant was diagnosed with non-Hodgkins lymphoma for which he received his first round of chemotherapy treatment between 1998 and 1999, under the care of Dr Tiley. He was admitted to hospital on 2 August 2002, due to a relapse, at which time there was no history of allergy noted by the hospital. Mr Marchant was re-admitted to hospital on 13 August 2002 to receive a second round of chemotherapy treatment, which was administered intravenously by a cannula inserted into his arm, under the care of Dr Lindeman. 10 In correspondence to the appellant, Dr Lindeman outlined the deterioration of the condition of Mr Marchant following the treatment. On 14 August 2002, Mr Marchant began experiencing breathing difficulties, leading to a diagnosis of pneumonitis. By the next day, he had developed haemoptysis and was monitored and treated accordingly. His condition continued to deteriorate, and on 18 August 2002, it was recorded that he had developed neutropenic sepsis. Mr Marchant died at 10.40pm that evening. 11 The death certificate, certified by Dr Williams, recorded the cause of death as: "(I) a) Hypersensitivity pneumonitis, days b) Chemotherapy for non-Hodgkins lymphoma, days
(II) Chronic airflow limitation secondary smoking" 12 The trial judge accepted Dr Lindeman's record of events and opinion. In particular, the trial judge noted that it was the doctor's opinion that the choice of chemotherapy administered to treat Mr Marchant the second time around was "entirely appropriate", that "[a]n allergic response to this chemotherapy was unpredictable" and that the course taken following the chemotherapy was consistent with the diagnosis that was made, namely, of hypersensitivity reaction to one of the chemotherapy agents. The trial judge accepted Dr Lindeman's conclusion that: "… Mr Marchant's death was directly consequent on the intentional administration of chemotherapy appropriate to his clinical condition, and given with his consent. The course of events was unpredictable and there was no way of predicting this unfortunate chain of events." (Emphasis added) 13 Dr Lindeman was of the opinion that the deterioration in Mr Marchant's condition was compounded by the development, recorded on the day of his death, of neutropenic sepsis. The doctor stated that "[h]is chronic airflow limitation related to previous smoking was a likely contributory factor to the extent of his hypoxia". The trial judge did not refer to this part of Dr Lindeman's opinion, although his Honour made a general observation, after referring to the above extract (set out at [11] above) in Dr Lindeman's report, that "I accept Dr Lindeman's opinion and make findings in accordance with it". 14 After reviewing the caselaw, his Honour concluded that in the circumstances that occurred here, there was "an accident" in accordance with the statement of the High Court in Federico's case. He said that the deceased went into hospital for treatment and, although the treatment itself was appropriate, he "[had] a violent reaction to parts of the drugs and [died]". 15 His Honour next considered that the "accident" was caused by "violent, visible and external means". His Honour explained his conclusion in these terms: "There is inserted into the deceased's arm a needle. Through that needle and directly fed into the veins the drug [sic]. The drug causes the reaction, the deceased dies … the insertion of a needle [and] the breaking of the skin by the insertion of a needle I would have thought was covered by the term violent, it is visible and external." 16 It followed on his Honour's finding that all the requirements of the policy were met.